IL18BP and metabolic dysfunction-associated steatohepatitis: Increasing IL-18BP amount or activity (a therapeutic option already clinically validated to treat rare systemic auto-inflammatory diseases44) represents interesting pharmacological perspectives to treat MASLD/MASH.